The Filing Desk

Alvotech vs TG Therapeutics

Alvotech ALVO · TG Therapeutics TGTX · Biotechnology

TG Therapeutics reported revenue of $616 million in fiscal 2025, about the same as Alvotech's $586 million in fiscal 2025. Alvotech's revenue grew 19.7% in its latest year, and TG Therapeutics' grew 87.3%. Alvotech had an operating margin of 13.3%, against 20.0% at TG Therapeutics. Free cash flow was −$115 million at Alvotech and −$25 million at TG Therapeutics.

Side by side

AlvotechTG Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$586M$616M
Revenue growth19.7%87.3%
Revenue growth a year, last 5 years54.5%398.6%
Gross margin59.8%83.7%
Operating margin13.3%20.0%
Net margin4.8%72.6%
Free cash flow−$115M−$25M
Free cash flow margin−19.6%−4.0%
Return on capital5.4%29.0%
Net debt to EBITDA9.7x0.4x
Dividends and buybacks$0M$91M
Change in diluted share count8.7%0.7%
Last close$4.29$64.88
P/E at the last close—96.8×
Insider trades, last 12 months—sold $437,650
Piotroski F-score3 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlvotechTG Therapeutics
Operating margin
Percent of revenue
AlvotechTG Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlvotechTG Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alvotech and TG Therapeutics pages.